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Summary
For the past several decades, we have witnessed the emergence of the obesity pandemic worldwide 
and, simultaneously, the increase of incidence of malignant diseases. The effects of obesity and overweight 
on cancer incidence, morbidity, and mortality started to be meticulously researched only recently. Accord-
ing to the epidemiological data analysis, the connection between obesity and increased risk of numerous 
cancers has been established. Estimations are that a change in lifestyle and diet can prevent 30-50% of 
malignant diseases. After smoking, obesity is the second largest preventable cause of cancer. Obesity af-
fects the quality of life and increases the risk of cancer recurrence and cancer-related mortality. By reduc-
ing body mass and avoiding gaining weight during adulthood, the risk of getting cancer is lowered. Nu-
merous studies have shown the beneficial effects of physical activity during and after cancer treatment. 
Obesity influences cancer development; however, the mechanisms responsible for it are still unclear. It is 
considered that chronic inflammation, caused by the overabundance of nutrients, increases the levels of 
inflammatory cytokines and immune cells. It has been discovered that adipocytes have an important en-
docrine role; they synthesize numerous hormones and adipocytokines, such as leptin and adiponectin. 
High levels of leptons and low levels of adiponectin can activate intracellular signaling pathways involv-
ing malignant cells’ development. An important part of cancer development can be attributed to insulin 
metabolism, insulin-like growth factors, and sex hormones.
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INTRODUCTION
Obesity is a complex multifactorial disease, 
which can be defined as an abnormal and exces-
sive accumulation of fat tissue in the body with a 
consequent adverse effect on the human body’s 
health. The body mass index (BMI) is the most 
commonly used scale to measure nutritional sta-
tus. It is calculated by dividing a person’s weight 
(in kilograms) by their height (meters) squared. 
BMI is expressed in units of kg/m2. According to 
WHO, BMI values fall into four basic categories. 
People with a BMI below 18.5 kg/m2 are consid-
ered underweight. Between 18.5 and 24.9 kg/m2 
are considered normal body weight, overweight 
more than 25 kg/m2, and obese with more than 30 
kg/m2. Obesity can be further subdivided into 
class I obesity with BMI 30-34.9 kg/m2, class II obe-
sity with BMI 35-39.9 kg/m2, and class III obesity 
with BMI> 40 kg/m2. Class III obesity is sometimes 
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categorized as extreme obesity. Complementing 
the BMI, waist circumference, and waist-hip ratio 
are increasingly used to assess body fat distribu-
tion. The waist-hip ratio is the number obtained 
by dividing the waist and hips circumference. 
Waist circumference is a better predictor of vis-
ceral adipose tissue than BMI in both genders. Ab-
dominal adiposity can vary significantly within a 
small range of BMI and total body fat. Excessive 
visceral adipose tissue is associated with de-
creased adiponectin levels, elevated levels of cyto-
kines (IL-6, TNF-α), insulin resistance, systemic 
inflammation (1). In 2015, there were an estimated 
603 million obese adults and 107 million obese 
children worldwide (2). WHO has extracted sev-
eral key facts on obesity; since 1975, worldwide 
obesity has nearly tripled, more than 1.9 billion 
adults or 39% of adults were overweight, and over 
650 million or 13% of adults were obese. Forty mil-
lion children under the age of 5 and over 340 mil-
lion children between the ages of 5 and 19 were 
obese or overweight—overweight and obese kill 
more people than underweight (3). In Croatia, ac-
cording to the 2015/2016 survey, 34.9% of children 
aged 8-9 were overweight and obese (4). The over-
all prevalence of overweight in Croatia is estimat-
ed at 38.11% and obesity at 20.34%. For men, the 
prevalence of overweight is 43.2%, obesity 20.1%, 
and for women, the prevalence of overweight 
33.6% and obesity 20.6% (5). Obesity has assumed 
pandemic proportions. The obesity pandemic can 
be explained by a drastic change in lifestyle and 
living environment in the last 30 years. Modern 
societies practice a sedentary lifestyle, consume 
processed, cheap, and high-calorie foods, live in 
urbanized and industrialized environments with 
massive use of mechanized transport. Obesity is 
associated with numerous diseases and condi-
tions such as type II diabetes mellitus, hyperten-
sion, hypothyroidism, dyslipidemia, stroke, coro-
nary heart disease, obstructive sleep apnea, chole-
lithiasis, osteoarthritis, and depression (6). 
Through an extensive review of the literature, 
many epidemiological studies have linked obesity 
to an increased risk of many cancer types. Obesity 
has been shown to increase the risk of oesopha-
geal adenocarcinoma, gastric cardia cancer, 
colorectal cancer, pancreatic cancer, liver cancer, 
and gall bladder cancer, endometrial cancer, post-
menopausal breast cancer, ovary, kidney, and thy-
roid cancers, meningioma, and multiple myeloma. 
Modern society pays a substantial economic and 
psychosocial price due to obesity. In 2008, total 
national spending caused by obesity and over-
weight in the U.S. was estimated at over $ 140 bil-
lion or nearly 10% of all medical expenses (7). 
Avoiding weight gain during adulthood may pro-
tect overweight and obese individuals from cer-
tain types of cancer. According to meta-analysis, 
weight gain during adulthood is associated with a 
higher risk of colon and kidney cancer and post-
menopausal women of breast, ovarian, and endo-
metrial cancers (8). There is also evidence that 
weight loss also reduces the risk of obesity-related 
cancers. Obese patients undergoing bariatric sur-
gery had a 45% lower risk of developing obesity-
related cancer in comparison with the obese con-
trol group (9).
The mechanisms by which obesity increases 
the risk of cancer are not completely clear. It is 
thought to be related to significant metabolic and 
hormonal disorders. Obesity is associated with 
changes in the metabolism of sex hormones, insu-
lin and insulin-like growth factor signaling, chron-
ic inflammation, and adipokine disorders.
Cancer is the second leading cause of death 
in the world. In 2018, the cancer occurrence rate 
was estimated at 18.1 million new cases and 9.6 
million cancer-related deaths. The most common-
ly diagnosed cancer was lung cancer (11.6% of 
new cases), followed by breast cancer (also 11.6% 
of cases), prostate cancer (7.1%), and colorectal 
cancer (6.1%). Lung cancer has the highest mortal-
ity rate and contributes to 18.4% of all cancer 
deaths. Colorectal cancer accounts for 9.2%, stom-
ach cancer for 8.2%, and liver cancer for 8.2% of 
total cancer deaths. Breast cancer is the most com-
mon cancer and the leading cause of cancer deaths 
among women (6.6% of all cancer deaths) (10). It is 
estimated that between 30 and 50% of all cancer 
and cancer-related deaths could be prevented by 
diet and lifestyle changes. The two most common 
modifiable causes of cancer are tobacco use and 
obesity/overweight. Other preventable risk factors 
that affect the incidence and mortality of cancer 
are alcohol consumption, diet, physical inactivity, 
occupation, infections, pollution, U.V., and ioniz-
ing radiation (11).
MECHANISMS
As stated above, obesity and overweight are 
risk factors for the occurrence of certain cancers. 
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There are several hypotheses on possible mecha-
nisms. Over the past decades, an association be-
tween rapid growth in obesity and type II diabetes 
mellitus has been noticed, with the finding of in-
sulin resistance, consequent hyperinsulinemia, 
and impaired glucose homeostasis in such pa-
tients. Further research has revealed insulin resis-
tance in various infections and acute immune con-
ditions, such as sepsis, HIV, hepatitis, rheumatoid 
arthritis (12,13,14,15).
Thus, it seems that metabolic tissues such as 
adipose tissue, liver, and muscles interacted with 
the immune system. The classic inflammatory re-
action is defined by pain, redness, heat, and swell-
ing. A different inflammatory response was found 
in obese individuals, and the term metainflamma-
tion was proposed. The trigger for an immune re-
sponse in obesity is a metabolic cell (adipocyte) in 
response to excessive nutrient intake. Full-spec-
trum of inflammatory cytokines is secreted in adi-
pose tissue, followed by increased numbers of 
macrophages, natural killer T cells, mast cells, and 
CD8/CD4 lymphocytes (16,17). In summary, obe-
sity-induced chronic, low to moderate inflamma-
tion, and nutrient-induced inflammatory response 
initiated by metabolic cells creates a specific mi-
lieu of various immune cells and proinflammatory 
cytokines. Chronic inflammatory microenviron-
ment can cause direct DNA damage by increasing 
oxidative stress, tumor promotion, and progres-
sion by promoting neoangiogenesis, growth, and 
invasion of tumor cells (18,19,20).
Gallstones are a common complication of 
obesity, which triples the risk of gallstones in 
women and doubles it in men, adults, and adoles-
cents (21). In obesity, the activity of cholesterol 
synthesis and secretion into bile is increased (22). 
Gallstones appear to carry the highest risk for 
gallbladder cancer with a relative risk of 4.9 (23). 
Chronic irritation of gallbladder mucosa caused 
by gallstones and deposition of calcium in the 
gallbladder wall (porcelain gallbladder) leads to 
dysplasia and can end with malignant transfor-
mation (24,25). In Barrett’s esophagus, prolonged 
acid exposure in gastroesophageal reflux disease 
(GERD) leads to chronic inflammation and re-
placement of healthy oesophageal epithelium 
with metaplastic columnar cells. Prolonged expo-
sure to gastric acid and bile salts to induce nitric 
oxide and reactive oxygen species, which causes 
double-strand breakage and oxidative DNA dam-
age. These events prompt metaplasia and dyspla-
sia to cancer sequence (26). The relative risk of ad-
enocarcinoma among patients with Barrett’s 
esophagus compared to the general population 
was 11.3, and the annual risk of adenocarcinoma 
was 0.12% (27).
A prime example of the association between 
chronic inflammation and cancer is liver cancer. 
Hepatocellular carcinoma is the most common 
form of primary liver cancer, the fifth most com-
mon type of cancer globally, and the third cause of 
cancer-related death in the world (28). Most hepa-
tocellular carcinoma cases are associated with 
chronic viral hepatitis caused by hepatitis B and C, 
excessive alcohol consumption, non-alcoholic ste-
atohepatitis, and hemochromatosis (29). During 
chronic viral infection, the host immune system 
often fails to eradicate the infection, culminating 
in a continuous cycle of necrosis and hepatocyte 
regeneration, increasing the likelihood of gene 
mutations in hepatocytes and initiates the prolif-
eration survival of the affected cells. Oxidative 
stress, inflammatory cells, and cytokines induce 
oxidative damage to DNA, DNA methylation, 
transcription, and activation of growth factors, 
thus accelerating hepatocarcinogenesis (30). In 
obese individuals, the inflammatory cascade and 
insulin resistance are thought to play a significant 
role in developing liver cancer (31).
Repeated flare-ups of inflammation of the 
colorectum’s mucous membranes in ulcerative 
colitis increase cancer’s likelihood by inducing 
oxidative DNA damage, DNA methylation, mic-
rosatellite instability, mutation of the p53 gene, 
and mitochondrial DNA, and inhibition of sup-
pressor oncogenes (32,33).
Another possible mechanism to explain the 
increased risk of cancer in obese individuals is the 
influence of various hormones and growth factors 
synthesized and released by adipocytes. These 
new hormones, or so-called adipocytokines, have 
a potentially important role in food intake and en-
ergy balance. The role of many adipocytokines is 
still unclear. The best known and most studied 
adipocytokine is leptin. Leptin is a 167-amino acid 
peptide hormone secreted by adipocytes and al-
lows communication between adipose tissue and 
the central nervous system. It binds to the leptin 
receptor (known as LEP-R or Ob-R) in presynaptic 
GABAnergic neurons of the hypothalamus, de-
creasing food intake and promoting energy con-
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sumption. During fasting, dieting, or uncontrolled 
type I diabetes, fat deposits are reduced, leptin 
levels in serum decrease, stimulate hunger, and 
reduce energy consumption—genetic deficiency 
of leptin results in massive obesity with extreme 
hyperphagia and reduced energy expenditure. 
The serum concentration of leptin is proportional 
to the amount of fat in the body. Therefore, higher 
leptin concentration should result in decreased 
food intake and raised energy expenditure, which 
is not the case in obese and overweight patients, 
suggesting a leptin resistance state. (34).
Several possible mechanisms for the devel-
opment of leptin resistance include genetic muta-
tions, impaired leptin transport across the blood-
brain barrier, dysregulation of leptin expression, 
hypothalamic inflammation (35). Besides insulin, 
leptin plays a vital metabolic role by decreasing 
hepatic glucose production, increasing insulin 
sensitivity, decreasing glucagon levels, decreasing 
insulin synthesis and secretion, and decreasing li-
pogenesis in adipose tissue (36). Leptin receptors 
are usually found in the brain but also in many 
peripheral organs Leptin activates numerous in-
tracellular signaling pathways like Jak/Stat, 
MAPK, PI3K/Akt, and SOCS pathways promote 
cancer cell growth and metastases. Increased ex-
pression of the ObR receptor has been detected in 
breast and gastrointestinal cancers and is associ-
ated with poorer prognosis (37).
Adiponectin is a protein hormone, and it is 
primarily synthesized in adipose tissue. Obese in-
dividuals generally have decreased adiponectin 
levels, while weight loss increases adiponectin 
levels. Hypoadiponectinemia is associated with 
insulin resistance, dyslipidemia, and atherosclero-
sis. It has a significant role in suppressing the ac-
tion of inflammatory cytokines and modulates 
natural killer cells. Unlike leptin, adiponectin ap-
pears to have anti-tumor effects. Attachment of 
adiponectin to AdipoR1 and AdipoR2 receptors 
increases AMPK phosphorylation and counteracts 
leptin signaling. In some cases, adiponectin can 
reduce migration and invasion of tumor cells, sup-
press breast cancer xenografts’ growth, and inhib-
it tumor neoangiogenesis (38). Some studies have 
found that low adiponectin levels are associated 
with an increased risk for gastric, prostate, and 
non-small cell lung cancer (39,40,41).
Estrogens are essential in adipose tissue dis-
tribution, body weight, energy expenditure, and 
metabolism. Studies have shown that estrogens 
play a significant role in the proliferation of the 
healthy and neoplastic epithelium and that they 
have carcinogenic effects in breast cancer develop-
ment. Estrogens have a carcinogenic effect on the 
cell in three ways: by stimulating cell proliferation 
via estrogen receptors and direct genotoxic effects 
by increasing mutation rates via activation of cy-
tochrome p450 and induction of aneuploidy (42). 
The vast majority of estrogens are produced in 
healthy, premenopausal women in the ovaries via 
aromatization of androstenedione to estrone and 
estradiol. However, in postmenopausal women 
and men, most estrogens are synthesized in ex-
tragonadal sites, mainly in adipose tissue from an-
drogenic precursors. Estrogen levels are propor-
tional, dependent on the amount of adipose tissue. 
Obesity is a known risk factor for the progression 
and development of breast cancer among post-
menopausal women. According to studies, the 
risk of death from breast cancer is 2.28 times great-
er for women classified as obese, and for each 5 kg 
gain in weight, breast cancer mortality is increased 
by 13%. In summary, obese and overweight wom-
en and women who gain weight are associated 
with higher breast cancer mortality (43). Besides 
breast cancer, high estrogen levels have been as-
sociated with an increased risk of endometrial and 
ovarian cancers (44,45).
Obesity and type II diabetes are closely re-
lated and show increased prevalence worldwide. 
Obese patients and diabetics have increased mor-
tality and incidence of numerous cancers. Diabe-
tes is a disease characterized by many metabolic 
disorders that contribute to cancer progressions 
such as hyperinsulinemia, dyslipidemia, hyper-
glycemia, elevated levels of free insulin-like 
growth factor I, changes in adipokine, and cyto-
kine secretion. Hyperinsulinemia or insulin resis-
tance is present in almost all individuals with type 
II diabetes and correlates positively with abdomi-
nal obesity (46). Many tumors express IGF-I, 
which is the ligand for IGF-IR. In animal models, 
high doses of IGF-I stimulates cancer growth and 
metastases (47). The insulin receptor (I.R.) is also 
overexpressed by many different cancers like 
breast, colon, lung, prostate, ovary, and thyroid 
cancers. It seems that hyperinsulinemia may con-
tribute to tumor growth and progression by bind-




Furthermore, epidemiological studies have 
shown a positive association between elevated c-
peptide levels (a marker of insulin secretion) and 
breast, colorectal and endometrial cancers 
(48,49,50).
Endometrial cancer and obesity
Traditionally, endometrial cancers are divid-
ed according to histology and disease outcome 
into two types. Type I tumors account for the ma-
jority of all endometrial cancers, mostly endome-
trioid adenocarcinoma. It often arises from endo-
metrial hyperplasia and is associated with higher 
estrogen levels. Type II tumors are predominantly 
serous, or clear-cell cancers, which are often de-
scribed as estrogen-independent from the atro-
phic endometrium. Type II tumors have a worse 
prognosis and less differentiation than type I tu-
mors. Among the risk factors for the development 
of type I endometrial cancer, there is an imbalance 
between estrogen and progesterone exposure, in-
cluding obesity and the use of unopposed estro-
gen therapy. A large study that included data 
from 24 cohort and case report studies, the aim 
was to clarify risk factors for the development of 
both types of endometrial cancer. Obese and over-
weight women are 2 to 4 times more likely to de-
velop type I endometrial cancer than normal body 
weight women. Extremely obese women (BMI>40 
kg/m2) have an even 7-fold increased risk of devel-
oping endometrial cancer. Surprisingly, type II 
endometrial cancers also occur two to three times 
more frequently in obese and overweight women 
(51). In summary, it appears that both types of en-
dometrial cancers have similar risk factor profiles, 
and both are associated with estrogenic and anti-
estrogenic exposure. Furthermore, obesity 
throughout life, including childhood and adoles-
cence, is associated with endometrial cancer risk. 
Additionally, weight gain after 18 increases the 
risk of endometrial cancer compared to women of 
stable body weight (52)
Oesophageal adenocarcinoma and obesity
According to the epidemiological data, there 
has been a considerable increase in oesophageal 
adenocarcinoma incidence over the last 35 years. 
Among white men, increases in the incidence of oe-
sophageal adenocarcinoma between 1975 and 2004 
were staggering 463% and 335% among white 
women in the United States (53). Survival rates of 
patients with oesophageal carcinoma continue to 
be low despite better supportive care and treatment 
options. Obesity is associated with an increased 
risk of oesophageal adenocarcinoma, GERD, and 
Barrett’s esophagus (54). Abdominal thickness in-
creases intra-abdominal pressure and consequently 
increases GERD’s propensity by deforming the 
lower oesophageal sphincter (55). An extensive 
analysis involving 12 epidemiological studies 
stressed an association of oesophageal adenocarci-
nomas and oesophagogastric junction adenocarci-
nomas with increasing BMI. Overweight and obese 
patients are twice as likely to develop oesophageal 
cancer than patients with normal body weight. Ex-
tremely obese patients (BMI >40kg/m2) have an al-
most fivefold higher risk of developing oesopha-
geal cancer than patients with BMI <25 kg/m2. Sim-
ilarly, an increase in BMI also increases the risk of 
developing oesophagogastric junction adenocarci-
nomas 2 to 3 times compared to a patient of normal 
body weight. The synergistic effect of obesity and 
GERD concerning oesophageal adenocarcinoma 
risk has also been demonstrated (56). Several po-
tential mechanisms explain the association between 
obesity and oesophageal cancer. The first mecha-
nism is direct or mechanical, where central obesity 
causes deformity of the oesophageal sphincter, in-
creases intragastric pressure, and increases hiatal 
hernia and GERD risk. The second mechanism is 
an indirect, proinflammatory, carcinogenic path-
way caused by adipose tissue’s highly metabolic 
and hormonal activity (57).
Gastric cancer and obesity
Gastric cancer is the fifth most commonly di-
agnosed cancer and the second leading cause of 
cancer-related death (10). According to anatomi-
cal localization of the tumor, gastric cancers are 
classified into gastric non-cardia cancer (GNCS) 
and gastric cardia cancer (GCC). Interestingly, a 
decrease in the incidence of gastric non-cardia 
cancer and an increase in gastric cardia cancer in-
cidence in western countries have been observed. 
Epidemiological studies have shown different eti-
ological causes between the two subtypes, ex-
plaining the discrepancy of incidences. Risk fac-
tors for GCC may be GERD, white race, male gen-
der, and tobacco smoking, while most GNCS can 
be linked to Helicobacter pylori infection, alcohol 
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consumption, tobacco smoking, and use of salt or 
salted, pickled food (58-61). The rising incidence 
of many cancers and the parallel epidemic of obe-
sity suggest an association between the two. A 
meta-analysis by Cheng et al. investigated the as-
sociation between BMI increase and GCC and 
GNCC and evaluated 24 prospective studies that 
included 41,791 patients. The meta-analysis re-
sults showed a positive association with gastric 
cardia cancer risk with an increased BMI (GCC; 
for overweight patients, SRR=1.21, and obese 
SRR=1.82). This meta-analysis found no associa-
tion between increased risk for GNCC develop-
ment and obesity (GNCC; for overweight patients, 
SRR = 0.93 and obese SRR = 1.00). It is likely that 
the biological mechanism by which obesity in-
creases gastric cardia cancer risk is similar to that 
of oesophageal adenocarcinoma (62).
Liver cancer and obesity
Primary liver cancer (PLC) is the sixth most 
common cancer globally and the second leading 
cause of cancer death in East Asia and sub-Saha-
ran Africa. According to data, primary liver cancer 
incidence has tripled in the United States in the 
last four decades (10). The literature data describes 
numerous risk factors such as chronic viral hepa-
titis (hepatitis B and C), liver cirrhosis, aflatoxins, 
non-alcoholic fatty liver disease, alcohol consump-
tion, smoking, obesity, diabetes mellitus. A meta-
analysis published in 2012 analyzed data from 
25337 liver cancer patients included in 26 prospec-
tive studies to assess the association between obe-
sity and the risk of primary liver cancer. Results 
showed that excess body weight and obesity were 
associated with an increased risk of PLC. Over-
weight people (BMI> 25 kg/m2) have a 48% higher 
risk of developing liver cancer than normal body 
weight subjects (SRR = 1.48). For obese individu-
als, this risk is twice as high (R.R. = 1.83). Sub-
group analysis showed that the positive associa-
tion between weight gain and liver cancer was in-
dependent of other risk factors. By stratifying the 
data for gender, it is observed that overweight 
males had a higher risk of PLC than overweight 
females (for males, SRR=1.42, for females, SRR= 
1.18). A similar difference is observed by compar-
ing the risk of PLC development for obese males 
(SRR=1.91) and women (SRR=1.55) (63).
The Liver Cancer Association Project collect-
ed and analyzed 14 prospective studies from 1.57 
million adults in the United States to investigate 
BMI, waist circumference, and type II diabetes 
with primary liver cancer risk, and identified 2162 
patients diagnosed with primary liver cancer. 
Their average age was 58.2 years, mean BMI 26.6 
kg/m2, average waist circumference 89.8cm, and 
prevalence of type 2 diabetes 6.5%. Compared 
with normal body weight, overweight has 21%, 
class I obesity 87%, class II obesity 142%, class III 
obesity 116% higher risk of liver cancer. The anal-
ysis results also showed that type II diabetes triple 
the risk of liver cancer (HR=2.85) (64). These stud-
ies have demonstrated a clear association between 
obesity and type II diabetes with an increased risk 
of developing liver cancer. Adiposity and type II 
diabetes share common mechanisms involved 
in hepatocellular carcinogenesis. The increased 
amount of adipose tissue in the liver causes fibro-
sis and cirrhosis of the liver, lipotoxicity, low-
grade chronic inflammation, and insulin resis-
tance (65). There is increasing evidence that both 
intestinal microbiota and activation of toll-like re-
ceptor (TLR4) by lipopolysaccharide (LPS) play a 
role in the promotion and proliferation of liver 
cancer (66). In obesity, alteration of gut microbiota 
increases deoxycholic acid levels in the entero-
hepatic circulation. Deoxycholic acid is known to 
cause DNA damage through oxidative stress, 
which provokes Ito cells in the liver to secrete 
 various inflammatory and tumor-promoting fac-
tors (67).
Renal cancer and obesity
As with many cancers, an increase in kidney 
cancer incidence has been observed; it could be as-
sociated with arterial hypertension, obesity, and 
smoking as risk factors (68). About 80-90% of all 
kidney cancers are renal cell carcinoma (RCC). Lo-
coregional and metastatic disease of kidney can-
cer is common at diagnosis because of a lack of 
early signs and symptoms in patients. In 2014, a 
comprehensive meta-analysis of 21 cohort studies 
was published with 15144 cases of kidney cancer 
and more than 9 million participants. The study 
demonstrated an increased risk of kidney cancer 
in obese and overweight patients. The relative risk 
of RCC in overweight patients was 1.28 and 1.77 in 
obese patients. Overweight and obese women had 
a slightly higher risk of RCC than men. The risk of 
RCC for men and women increased by 4% and 
5%, respectively, for each 1kg/m2 increment (69).
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An extensive 2014 study analyzed data from 
156.774 participants over 10.8 years on the rela-
tionship between hypertension, obesity, and kid-
ney cancer. Data showed an excessive risk of kid-
ney cancer in both sexes with increasing blood 
pressure. Also, the association between obesity 
and kidney cancer is independent of its associa-
tion with hypertension or smoking (70).
The mechanism by which obesity increases 
the risk of kidney cancer is not yet clear. A possi-
ble explanation is the complex interaction of insu-
lin, increased insulin-like growth factors, sex hor-
mones, and adipokines. Insulin-like growth factor 
and its pathway are essential for the von Hippel-
Lindau (VHL) tumor suppressor gene. In its defi-
ciency, an autosomal dominant syndrome called 
VHL syndrome develops, marked by multiple re-
nal cell tumors (71).
Pancreatic cancer and obesity
Pancreatic cancer, as kidney cancer has few 
early signs and symptoms, is diagnosed at late 
stages and has a 5-year survival of only 7% (72). 
The incidence of pancreatic cancer is exceptionally 
high in Western societies and increasing over the 
last few decades. Obesity is hypothesized to pro-
mote the growth of pancreatic cancer. Based on 
the analysis of 14 cohort studies on 846340 indi-
viduals with 2135 cases of pancreatic cancer, Gen-
kinger et al. concluded that BMI is positively as-
sociated with pancreatic cancer risk. Obese indi-
viduals had a 47% higher risk of pancreatic cancer 
(R.R. = 1.47).
Furthermore, the analysis also found a posi-
tive association between being overweight in early 
adulthood and being obese at baseline, with a 54% 
increased risk of pancreatic cancer (R.R. = 1.54). 
Also, an increase in BMI of more than 10kg/m2 
compared to BMI in early adulthood has been 
shown to increase the risk of pancreatic cancer by 
40% compared to persons of stable body weight 
(73). Multiple mechanisms and pathways are 
thought to be responsible for the increased risk of 
pancreatic cancer in the obese, such as insulin re-
sistance, secretion, and synthesis of numerous 
hormones and adipocytokines, environmental ex-
posure to carcinogens and mutagens in food, and 
decreased physical activity leading to energy im-
balance (74).
Breast cancer and obesity
Breast cancer is the second most common can-
cer globally and the second cause of cancer-related 
death in more developed regions after lung cancer. 
Understanding how obesity affects breast cancer 
has important implications for public health. A 
comprehensive systematic review and meta-analy-
sis published in 2007 analyzed data from 141 arti-
cles and included 282137 cancer cases to determine 
the risk of breast cancer associated with a BMI in-
crease of 5kg/m2. In women, a meta-analysis found 
a strong association with BMI increase and en-
dometrial (R.R. = 1.59), gallbladder (R.R. = 1.59), 
esophagus (R.R. = 1.51), and kidney cancers (R.R. = 
1.34). A slightly lower positive correlation was 
found between weight gain by more than> 5kg/m2 
and leukemia, pancreatic, thyroid, and postmeno-
pausal breast cancers. The relative risk for post-
menopausal breast cancer was 1.12, which means 
that every 5 unit increase in BMI is associated with 
a 12% increase in risk (75).
Earlier studies have noted a different associa-
tion between obesity and menopausal status. In 
obese premenopausal women, the risk of pre-
menopausal breast cancer was lower than that of 
normal-weight women. In contrast, in obese post-
menopausal women, studies have reported an in-
creased risk of postmenopausal breast cancer. 
(75,76). It has also been observed that the use of 
postmenopausal hormone therapy can modify the 
association between postmenopausal breast can-
cer and obesity. Munsell et al. published in 2013 a 
comprehensive meta-analysis with an aim to ana-
lyze and evaluate the relationship between BMI, 
menopausal status, and breast cancer according to 
breast cancer subtype and the use of hormone re-
placement therapy. Twenty-two articles with 
17407 participants analyzed the relationship be-
tween premenopausal breast cancer and body 
mass index. Overweight women (BMI 25-29.9 kg/
m2) were associated with modestly reduced risk of 
5% (risk ratio, RR=0.95) and obese women (BMI 
>30 kg/m2) with 17% reduced risk of premeno-
pausal breast cancer (RR=0.83). While comparing 
obesity with breast cancer subtype, an association 
with E.R. positive/P.R. positive (R.R. = 0.78) but 
not with E.R. negative/P.R. negative cancer (R.R. = 
1.06) was observed. In analyzing the relationship 
between obesity and postmenopausal breast can-
cer, the authors included 39 articles comprising 
Lib Oncol. 2020;48(2-3):89–102
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59185 participants with breast cancer. Overweight 
and obese women were associated with a 10% and 
18% increased risk of postmenopausal breast can-
cer, respectively. Similar to premenopausal breast 
cancer, only E.R. positive / P.R. positive breast 
cancer has been shown to be associated with obe-
sity. A 40% higher risk of developing postmeno-
pausal breast cancer due to obesity was observed 
in this subtype of breast cancer (R.R. = 1.39), while 
E.R. negative/P.R. negative postmenopausal 
breast cancer showed no association with obesity 
(RR=0.98). Postmenopausal women who have 
never taken estrogen-progestin therapy were also 
found to be at higher risk of developing breast 
cancer than normal-weight women (R.R. = 1.42). 
Among obese ever users of estrogen-progestin 
therapy, association with an increased risk of 
postmenopausal cancer has not been found 
(RR=0.98) than a normal-weight woman (77). In 
conclusion, a meta-analysis showed that obese 
women have a 20% reduction of hormone-recep-
tor-positive premenopausal breast cancer relative 
risk and 20-40% increased risk of hormone-recep-
tor-positive postmenopausal breast cancer in com-
parison with normal BMI women. It appears that 
the risk ratio is minimized for hormone receptor-
negative breast cancer and postmenopausal breast 
cancer among women using estrogen-progestin 
therapy.
Obesity is also a risk factor for breast cancer 
in men. In 2014, Brinton et al. evaluated 11 case-
control and ten cohort investigations with 2405 
breast cancer cases in men and 52013 control sub-
jects to identify risk factors. Compared with men 
of normal body weight, obese men had a 30% 
higher risk of developing breast cancer (OR = 
1.35), almost identical to the postmenopausal 
breast cancer risk. The highest risk for developing 
breast cancer was observed in patients with Kline-
felter syndrome (OR = 24.7) and gynecomastia 
(OR = 9.78) independently of BMI. Both Klinefelter 
syndrome and gynecomastia are linked with es-
trogen excess (78).
The biological mechanism that explains the 
association between obesity and breast cancer has 
been linked to the metabolism and action of sex 
hormones, most notably estrogen. Estradiol and 
estrone are elevated in postmenopausal obese 
women because they are secreted by adipose tis-
sue via aromatization of androgenic precursors. 
On the other hand, obesity is associated with an-
ovulation, thus explaining the lower levels of cir-
culating estrogen in premenopause (79). The low-
er risk of breast cancer in patients receiving hor-
mone therapy is explained by higher circulating 
estrogen levels and minimizing adipose tissue es-
trogen production.
Biliary tract cancer and obesity
Biliary tract cancer can be divided into two 
categories; more common gallbladder cancer (GBC) 
and less common extrahepatic bile duct cancer 
(EBDC). Gallbladder cancer is the sixth most com-
mon gastrointestinal tract cancer. It is character-
ized by late diagnosis and poor prognosis; the 
five-year survival of gallbladder cancer limited to 
gallbladder mucosa is only 32%, while in the case 
of advanced gallbladder cancer, the one-year sur-
vival is merely 10% (80). Because of the impor-
tance of primary prevention, it is important to 
identify modifiable risk factors. Some early obser-
vational studies have shown an association be-
tween gallbladder cancer and increased BMI with 
inconsistent results. In a large meta-analysis from 
2016, Li and colleagues investigated the associa-
tion between overweight and obesity and biliary 
tract cancer risk. More than eleven and a half mil-
lion participants were included in the meta-analy-
sis, including 6733 patients with gallbladder can-
cer and 5798 patients with extrahepatic duct can-
cer. Results showed that excessive body weight is 
significantly associated with an increased risk of 
both GBC and EBDC. Among overweight patients, 
the risk of GBC and EBDC was 17% and 26% high-
er than normal-weight participants. For obese pa-
tients, the risk was higher; GBC’s risk was 62%, 
and the risk of EBDC was 48%. The study showed 
that the increased risk is more pronounced in 
overweight and obese women and European pop-
ulations (81). The association between cholelithia-
sis and gallbladder cancer has been known for de-
cades, and adiposity is one of the major factors 
that increase gallstone formation. A hypothesis is 
that chronic inflammation, trauma, and infection 
can cause epithelial dysplasia and adenocarcino-
ma. Other possible mechanisms include increased 
levels of sex and metabolic hormones (80).
Colorectal cancer and obesity
Modifiable risk factors for one of the most 
common cancers globally, colorectal cancer, in-
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clude obesity, smoking, physical inactivity, and a 
low-fiber/high-fat diet. With the increasing inci-
dence of obesity worldwide, understanding the 
correlation between colorectal cancer and obesity 
is becoming increasingly important. The meta-
analysis published in 2013 included over 9 million 
participants and 90,000 cases of colorectal cancer, 
intending to establish an association between obe-
sity, central adiposity, and risk of colorectal can-
cer. Obesity was measured using BMI and central 
adiposity by measuring waist circumference. 
Overall results showed a positive association be-
tween obesity and colorectal cancer, and the risk 
was 30% higher for obese compared to normal-
weight individuals. Higher waist circumference 
has also been shown to carry a higher risk of can-
cer (R.R. = 1,455). Analysis of the data stratified by 
anatomical localization implies that elevated BMI 
and W.C. values caused an equally increased risk 
for rectal and colon cancers. Stratifying by sex, the 
risk for colorectal cancer in obese men was higher 
than in obese women (46% vs. 15%) (82). As with 
other cancers, the exact mechanism of the impact 
of obesity on cancer development is not yet clear. 
Two possible hormonal mechanisms are suggest-
ed: insulin / insulin-like growth factor (IGF) axis 
and adipokines. High levels of total IGF1 are as-
sociated with an increased risk of advanced 
colorectal adenoma and cancer. Adipocytes could 
also promote cancer proliferation by the secretion 
of adipokines such as adiponectin and leptin, 
which are associated with the risk of colorectal 
cancer (83,84).
Benefit from weight loss  
and cancer risk reduction
Evidence for an association between cancer 
and obesity was predominantly obtained from 
studies that determined excess body weight and 
weight gain, rather than studies that linked weight 
loss to a reduced risk of cancer. A small number of 
studies have compared weight loss and cancer 
risk and distinguish unintentional from intention-
al weight loss. Unintentional weight loss is often a 
sign of underlying health problems. It often hap-
pens that weight loss itself is challenging to sus-
tain over several years. Preclinical studies have 
proven that weight loss can reduce cancer inci-
dence by reducing oxidative damage to DNA, im-
proving DNA repair, and affecting hormonal 
pathways (85).
Avoiding gaining weight during adulthood 
is associated with reducing kidney and colon can-
cer risk and in postmenopausal women with a risk 
reduction of breast, ovarian, and endometrial can-
cer (86).
The most robust evidence linking weight loss 
to a reduced risk of cancer comes from studies 
that followed patients who underwent bariatric 
surgery. Several studies have shown that weight 
loss after bariatric surgery statistically significant-
ly reduces cancer risk (87,88).
According to one study that compared the 
risk of endometrial cancer in postmenopausal 
women who had stable body weight (+/- 5%) and 
women with intentional weight loss (>5%), results 
showed that women with weight loss had a 30% 
lower risk of endometrial cancer. Analyzing the 
subgroups, the most significant benefit in reduc-
ing endometrial cancer risk was among obese 
women who lost weight (H.R. = 0.44) (89).
Impact of obesity on cancer survivorship
There is little data on the impact of obesity on 
cancer survival; most of the evidence comes from 
patients diagnosed with breast, colorectal, and 
prostate cancer. Research has shown that obesity 
affects the deterioration of life quality, higher rates 
of cancer recurrence and mortality, and increased 
risk for common adverse treatment effects.
In a cohort study conducted in 2003, exces-
sive body mass was associated with increased 
death rates for all cancers combined and cancers 
at multiple specific sites (90).
Obese men who have prostate cancer have a 
higher risk of aggressive and fatal disease, a high-
er mortality rate, a higher risk of relapse, and it is 
initially more challenging to diagnose and detect 
prostate cancer (91,92). In breast cancer survivors, 
overweight and obesity are associated with an in-
creased risk of cancer-related lymphedema (90).
The beneficial effects of exercise in oncology 
patients should not be overlooked. Many studies 
have shown the beneficial effects of physical activ-
ity during and after cancer treatment. Exercise is 
associated with improvements in quality of life, 
physical function, and psychosocial outcomes. In 
breast and colon cancer survivors, higher physical 
activity is associated with a lower disease recur-





Cancer is a complex disease of pandemic pro-
portions, caused by the interaction of a number of 
genetic and environmental factors. A large pro-
portion of cancers can be related to risk factors 
such as obesity, tobacco, alcohol. So far, several 
possible mechanisms have been discovered that 
could explain the effect of obesity on the initiation 
and promotion of malignant cells. Further re-
search is essential to discover how some cancers 
are more obesity-related than others. More efforts 
are needed from the world community to educate 
the population about the risks and consequences 
of being overweight. The investing in prevention 
of obesity, smoking, and alcohol consumption 
while encouraging a healthy diet and exercise 
would reduce the pressure on health systems and 
bring significant economic and psychosocial ben-
efits. According to the evidence, it is recommend-
ed to increase physical activity and avoid gaining 
weight for cancer patients. Obese people are ad-
vised to lose weight to reduce cancer risk.
Further research is needed to understand the 
complexity of immune, metabolic, and hormonal 
mechanisms of obesity and their impact on cancer 
development and progression. It is essential to in-
vestigate therapeutic interventions on weight and 
energy balance, the impact of consuming better 
quality food, increased physical activity on cancer 
risk, disease recurrence, and mortality. Literature 
provides little data about obesity effects on the 
therapy response, cancer recurrence, and long-
term outcomes. Effective therapeutic protocols 
optimizing energy consumption, exercise, and 
weight balance are needed for patients at risk of 
cancer or already have cancer.
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F. Cmrečak, I. Andrašek, V. Gregov i L. Beketić-Orešković
Proteklih nekoliko desetljeća svjedočimo pandemiji pretilosti u cijelom svijetu i paralelnom porastu incidencije zlo-
ćudnih bolesti. Utjecaj pretilosti i prekomjerne tjelesne mase na incidenciju, morbiditet i mortalitet od raka tek u zadnjih 
nekoliko godina se počinje detaljnije istraživati. Prema analizama epidemioloških podataka, utvrđena je povezanost preti-
losti s povećanim rizikom od nastanka mnogih tipova zloćudnih bolesti. Procjenjuje se da je oko 30-50% zloćudnih bolesti 
moguće prevenirati promjenom načina života i dijetom. Nakon pušenja, pretilost je drugi vodeći preventabilni uzrok raka. 
Pretilost utječe na kvalitetu života, povećani rizik od povrata zloćudne bolesti i mortaliteta. Smanjenje tjelesne mase i izbje-
gavanje debljanja u odrasloj dobi se povezuje sa smanjenim rizikom od zloćudnih bolesti. Mnoge studije su pokazale blago-
tvorne učinke redovite tjelesne aktivnosti tijekom i nakon liječenja raka. Točni mehanizmi utjecaja pretilosti na razvoj 
 zloćudnih bolesti još nisu jasni. Smatra se da postoji povezanost s kroničnom upalom uzrokovanom pretjeranim unosom 
nutrijenata i posljedičnim povećanim razinama inflamatornih citokina i imunosnih stanica. Otkriveno je da adipociti imaju 
važnu endokrinu ulogu te sintetiziraju brojne hormone i adipocitokine, među kojima su najistraživaniji leptin i adiponektin. 
Visoke razine leptina i niske razine adiponektina mogu aktivirati intracelularne signalne puteve povezane s pojavom 
 zloćudnih stanica. U razvoju raka važnu ulogu može imati i metabolizam inzulina, te inzulinu-slični faktori rasta i spolni 
hormoni.
Ključne riječi: pretilost, rak, mehanizmi
